• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Top 20 Research Studies of 2022 for Primary Care Physicians
This article summarizes the top 20 research studies of 2022 identified as POEMs (patient-oriented evidence that matters), excluding COVID-19. Statins for primary prevention of cardiovascular disease produce only a small absolute reduction in a person's likelihood of dying (0.6%), having a myocardial infarction (0.7%), or having a stroke (0.3%) over three to six years. Supplemental vitamin D does not reduce the risk of a fragility fracture, even in people with low baseline vitamin D levels or a previous fracture. Selective serotonin reuptake inhibitors are preferred medical therapy for panic disorder, and patients who disco...
Source: American Family Physician - April 13, 2023 Category: Primary Care Authors: Roland Grad Mark H Ebell Source Type: research

Hypertensive Emergency and Stroke With Medication Interaction: A Case Report on Metoprolol and Duloxetine
No abstract available
Source: Journal of Clinical Psychopharmacology - July 1, 2022 Category: Psychiatry Tags: Letters to the Editors – Case Reports Source Type: research

Effect of Duloxetine for the Treatment of Chronic Central Poststroke Pain
Conclusions Our findings suggest that duloxetine can be effective for managing CPSP.
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Original Articles Source Type: research

Treatment of Poststroke Pathologic Laughing With Duloxetine: A Case Series
Conclusions This case series demonstrates that duloxetine could attenuate pathologic laughing exhibited by stroke patients; however, further randomized controlled studies are necessary to validate our findings.
Source: Clinical Neuropharmacology - March 1, 2019 Category: Neurology Tags: Case Reports Source Type: research

The Search for Treatments for Veterans With Major Depression —Of Paramount Importance, yet Still Elusive
Remission rates in patients with major depressive disorder (MDD) remain unacceptably low. From the 28% to 33% remission rate in the Sequenced Treatment Alternatives to Relieve Depression (STAR-D*) Study after treatment with the selective serotonin reuptake inhibitor citalopram to the more recent Predicting Response to Depression Treatment (PReDICT) Study of treatment-naive patients with depression treated with escitalopram, duloxetine, or cognitive-behavioral therapy (CBT), with remission rates of approximately 50%, it is clear that a sizable number of patients with depression do not achieve remission, the universally ackn...
Source: JAMA Psychiatry - June 27, 2018 Category: Psychiatry Source Type: research

Efficacy and tolerability of pharmacotherapy for post-stroke depression: a network meta-analysis.
Conclusions: Paroxetine is probably the best option to consider for patients with PSD. To get a quicker relief of depression, duloxetine might be useful for its rapid onset of antidepressant action. The tolerability was comparable among all the antidepressants. But more high-quality RCTs are needed. PMID: 29805769 [PubMed]
Source: Oncotarget - May 31, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Treatment of Depression With Duloxetine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes
We report a case in which an adult patient with MELAS and comorbid major depressive disorder demonstrated excellent response to the selective serotonin-norepinephrine reuptake inhibitor medication duloxetine.
Source: Clinical Neuropharmacology - May 1, 2018 Category: Neurology Tags: Case Reports Source Type: research

Pages: 1  2